From Early-Feasibility Data to Reimbursement: Building a Latin America MedTech Evidence Narrative

An early-feasibility study is often planned as a regulatory milestone: demonstrate that a procedure can be performed, identify safety signals, and learn what must change before a larger study. For MedTech founders and regulatory directors, that is necessary but incomplete. The same study can also become the foundation of a market-access narrative if its endpoints, comparators, resource use, and implementation context are chosen with future decision-makers in mind.

Latin American coverage systems are not uniform. Brazil, Colombia, and Mexico have used health technology assessment in coverage processes, but the role of HTA, the decision pathway, and the level of transparency vary by country and payer. A sponsor should therefore avoid promising reimbursement from a small feasibility study. The practical goal is to create evidence that answers the next payer question and can be extended with local data.

Why regulatory clearance is not reimbursement evidence

Regulatory review asks whether a technology is acceptably safe, performs as intended, and is supported for its proposed use. A payer or hospital committee asks a broader question: does adopting this technology improve outcomes enough to justify its total cost compared with the current pathway?

That difference changes the evidence plan. A technically successful procedure may still face adoption barriers if it increases procedure time, requires training, creates consumable waste, or shifts costs between departments. Conversely, a device with a modest clinical effect may be attractive if it reduces avoidable admissions, shortens recovery, or makes a scarce specialist service available in more locations.

Start by writing a value hypothesis in plain language: For which patients, compared with what current practice, will this technology change an outcome that matters to the health system? Then identify which parts of that hypothesis the early-feasibility study can test and which require later comparative or real-world evidence.

Translate early-feasibility endpoints into payer questions

Early-stage endpoints should remain ethical and scientifically realistic, but they can be selected to preserve a line of sight to market access. A useful endpoint map includes four layers:

• Patient outcomes: safety events, symptom change, functional status, quality of life, recovery time, and the need for repeat intervention.
• Clinical performance: technical success, procedure completion, accuracy, reliability, and the learning curve for trained users.
• Resource use: procedure duration, length of stay, imaging or laboratory requirements, staff time, consumables, readmissions, and follow-up visits.
• Implementation: training hours, site infrastructure, workflow changes, patient selection, adherence, and reasons for failure or conversion to standard care.

For a leading MedTech startup, the value is not in collecting every possible variable. It is in collecting a small, consistent set that explains both clinical benefit and the pathway required to deliver it. Define measurement timing, source data, missing-data rules, and the minimum clinically meaningful change before the first participant is enrolled.

Build a three-layer evidence package for Latin America

Layer one is clinical evidence. Combine the feasibility study with a transparent review of literature, comparable technologies, and relevant clinical experience. Explain where the population, practice setting, and comparator differ from other jurisdictions. International clinical-evaluation guidance emphasizes that evidence should be appraised for relevance, quality, applicability, and bias rather than simply counted.

Layer two is economic evidence. A full cost-effectiveness model may be premature, but a sponsor can build a budget-impact-ready data set. Capture the intervention cost, staff time, facility use, complications, follow-up, and avoided or added services. Report assumptions separately from observed data. This makes later adaptation to local prices and epidemiology more credible.

Layer three is implementation evidence. Document who can deliver the intervention, what training is required, which facilities are suitable, and how the pathway works in routine practice. Latin American HTA literature highlights the need for locally useful evidence, including real-world evaluations and information that reflects how technologies are implemented in specific settings.

Make the evidence portable but locally credible

Use a modular evidence architecture. Keep a core clinical-evaluation report, protocol synopsis, endpoint definitions, data dictionary, and economic model structure stable. Add country annexes for epidemiology, comparators, unit costs, care pathways, regulatory status, and decision criteria. This avoids rewriting the science while recognizing that “standard care” and affordability are local concepts.

For Brazil, prepare to explain how clinical and economic evidence fits the country’s HTA-informed public coverage environment. For Colombia, distinguish between having relevant HTA capacity and assuming that every recommendation is applied systematically. For Mexico, map the intended decision-maker and the evidence format it expects rather than treating a national label as a universal access decision. Across markets, a payer interview plan can test whether the proposed endpoints reflect real procurement and coverage questions.

Do not hide uncertainty. A staged access proposal can be more credible than an inflated claim: define the population, establish an outcomes-monitoring period, agree on a reassessment trigger, and specify what additional evidence will be generated. Any managed-entry or risk-sharing concept must be developed with the relevant payer or provider; it should not be presented as an automatic route to coverage.

FAQ: early-feasibility evidence and reimbursement

Can a first-in-human study prove reimbursement value?

Usually not by itself. It can establish feasibility, early safety, performance, and the data-collection process needed for a comparative or real-world evidence program. Sponsors should describe it as a foundation for value evidence, not as a guarantee of coverage.

Which endpoint is most important to payers?

There is no universal endpoint. The strongest endpoint is one that links a meaningful patient or clinical outcome to a change in resource use or care delivery. The right choice depends on the condition, comparator, decision-maker, and local pathway.

How can sponsors avoid duplicating studies in each country?

Use a shared core protocol and data dictionary, then add country-specific annexes and analyses. Standardize definitions and follow-up while collecting local cost, epidemiology, workflow, and implementation data needed for each market-access decision.